内皮素受体拮抗剂治疗肺动脉高压症临床评价

目的：伴随对肺动脉高压症发病机制的解释，一类内皮素受体桔抗剂于近期问市，本文阐述其在治疗肺动脉高压症的进展与临床评价，方法：采用国内、外文献综述方法。结果及结论：内皮素受体拮抗剂近年来进展迅猛，其抑制ET-1的收缩血管和促进细胞增殖作用，使动脉高压和心力衰竭问题已不再难于逾越，成为解脱肺动脉高压症之门一把金“药匙”．

Clinical Evaluation on Endothelin Receptor Antagonist for Hypertensive Pulmonary Vascular Disease

OBJECTIVE： With the clarifying of the pathogenic mechanism of pulmonary arterial hypertension, a new endothelin receptor antagonist has become available in the market recently. The advances and clinical evaluation of endothelin receptor antagonist were discussed in this paper. METHODS ： The pertinent literatures in recent years at home and abroad were reviewed. RESULTS ＆ CONCLUSION： Advance in endothelin receptor antagonist was rapid in recent years, and its inhibition on vasoconstrietion of endothelin - 1 and promotion on cell proliferation make it possible for treatment of arterial hypertension and cardiac insufficiency, which has become a golden “drug key” toward treatment for hypertensive pulmonary vascular disease.